The role of endothelial function and its assessment in rheumatoid arthritis

Nature Reviews Rheumatology

Volumn 6, Issue 5, 2010, Pages 253-261

  Khan, Faisel ^a   Galarraga, Bernat ^a   Belch, Jill J F ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; METHOTREXATE;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DOSE RESPONSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; LIFE EXPECTANCY; LOW DRUG DOSE; MUSCLE STIFFNESS; PAIN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SMOKING;

ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; RISK FACTORS;

EID: 77951978805     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.44     Document Type: Review

References (103)

1. Van Doornum, S., McColl, G. & wicks, I. P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 46, 862-873 (2002).
2. Myllykangas-Luosujärvi, R. A., Aho, K. & Isomäki, H. A. Mortality in rheumatoid arthritis. Semin. Arthritis Rheum. 25, 193-202 (1995).
3. Solomon, D. H. et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann. Rheum. Dis. 65, 1608-1612 (2006).
4. Van Doornum, S., Jennings, G. L. & Wicks, I. P. Reducing the cardiovascular disease burden in rheumatoid arthritis. Med. J. Aust. 184, 287-290 (2006).
5. Belch, J. J., McSwiggan, S. & Lau, C. Macrovascular disease in systemic sclerosis: the tip of an iceberg? Rheumatology 47 (Suppl. 5), 16-17 (2008).
6. Watson, D. J., Rhodes, T. & Guess, H. A. Allcause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J. Rheumatol. 30, 1196-1202 (2003).
7. Kvalvik, A. G., Jones, M. A. & Symmons, D. P. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand. J. Rheumatol. 29, 29-37 (2000).
8. Aviña-Zubieta, J. A. et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 59, 1690-1697 (2008).
9. Solomon, D. H. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107, 1303-1307 (2003).
10. Maradit-Kremers, H. et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 52, 402-411 (2005).
11. Goodson, N. J. et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 46, 2010-2019 (2002).
12. van Halm, V. P. et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis. 66, 184-188 (2007).
13. Nielen, M. M. et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum. 50, 2423-2427 (2004).
14. Nurmohamed, M. T. Cardiovascular risk in rheumatoid arthritis. Autoimmun. Rev. 8, 663-667 (2009).
15. Rojas-Villarraga, A. et al. Risk factors associated with different stages of atherosclerosis in Colombian patients with rheumatoid arthritis. Semin. Arthritis Rheum. 38, 71-82 (2008).
16. Sokka, T. et al. Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum. 59, 42-50 (2008).
17. Han, C. et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J. Rheumatol. 33, 2167-2172 (2006).
18. Panoulas, V. F. et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 47, 1286-1298 (2008).
19. Panoulas, V. F. et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 46, 1477-1482 (2007).
20. Dursunoglu, D. et al. Lp (a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol. Int. 25, 241-245 (2005).
21. Gonzalez, A. et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann. Rheum. Dis. 67, 64-69 (2008).
22. Escalante, A., Haas, R. W. & del Rincón, I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch. Intern. Med. 165, 1624-1629 (2005).
23. Chung, C. P. et al. Inflammation-associated insulin resistance: differential Effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 58, 2105-2112 (2008).
24. DeMaria, A. N. Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am. J. Cardiol. 89 (Suppl. 1), 33-38 (2002).
25. Johnsen, S. P. et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch. Intern. Med. 165, 978-984 (2005).
26. García-Gómez, C. et al. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur. J. Clin. Invest. 38, 686-692 (2008).
27. del Rincón, I., O'Leary, D. H., Haas, R. W. & Escalante, A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum. 50, 3813-3822 (2004).
28. rd et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 56, 820-830 (2007).
29. Ridker, P. M. et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 281, 1817-1821 (1999).
30. Roubenoff, R. et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum. 40, 718-722 (1997).
31. van Ede, A. E. et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 41, 658-665 (2002).
32. Choi, H. K., Hernán, M. A., Seeger, J. D., Robins, J. M. & wolfe, F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359, 1173-1177 (2002).
33. Gonzalez-Gay, M. A. et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 57, 125-132 (2007).
34. Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000). (Pubitemid 30165206)
35. Ku, I. A., Imboden, J. B., Hsue, P. Y. & Ganz, P. Rheumatoid arthritis: a model of systemic inflammation driving atherosclerosis. Circ. J. 73, 977-985 (2009).
36. Gonzalez-Juanatey, C. et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 57, 287-293 (2007). (Pubitemid 47164092)
37. Salmon, J. E. & Roman, M. J. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am. J. Med. 121 (Suppl. 1), S3-S8 (2008).
38. Dixon, W. G. & Symmons, D. P. What effects might anti-TNFα treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFα in cardiovascular pathophysiology. Ann. Rheum. Dis. 66, 1132-1136 (2007).
39. Gonzalez, M. A. & Selwyn, A. P. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am. J. Med. 115 (Suppl. 8A), 99S-106S (2003).
40. Devaraj, S., Yun, J. M., Adamson, G., Galvez, J. & Jialal, I. C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc. Res. 84, 479-484 (2009).
41. Gonzalez-Juanatey, C. et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am. J. Med. 114, 647-652 (2003).
42. Methe, H. & weis, M. Atherogenesis and inflammation--was Virchow right? Nephrol. Dial. Transpl. 22, 1823-1827 (2007).
43. Mäki-Patäjä, K. M. et al. Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction. Int. J. Cardiol. 129, 399-405 (2008).
44. Ito, A. et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99, 3092-3095 (1999).
45. Khan, F. et al. Impaired microvascular function in normal children: Effects of adiposity and poor glucose handling. J. Physiol. 551, 705-711 (2003).
46. Halcox, J. P. et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 106, 653-658 (2002).
47. Kumeda, Y. et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum. 46, 1489-1497 (2002).
48. Gonzalez-Gay, M. A. et al. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J. Rheumatol. 32, 1219-1223 (2005).
49. del Rincón, I. et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subject. Arthritis Rheum. 48, 1833-1840 (2003).
50. del Rincón, I., Freeman, G. L., Haas, R. w., O'Leary, D. H. & Escalante, A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum. 52, 3413-3423 (2005).
51. Mäki-Patäjä, K. M. et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy. Circulation 114, 1185-1192 (2006).
52. Galarraga, B., Khan, F., Kumar, P., Pullar, T. & Belch, J. J. Etanercept improves inflammationassociated arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 48, 1418-1423 (2009).
53. Ludmer, P. L. et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315, 1046-1051 (1986).
54. Khan, F. & Coffman, J. D. Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon. Circulation 89, 1183-1188 (1994).
55. Anderson, T. J. et al. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26, 1235-1241 (1995).
56. Shechter, M. et al. Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease. Int. J. Cardiol. 134, 52-58 (2009).
57. Gokce, N. et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J. Am. Coll. Cardiol. 41, 1769-1775 (2003).
58. Karatzis, E. N. et al. Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation. Am. J. Cardiol. 98, 1424-1428 (2006).
59. Staniloae, C. et al. Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. Cardiology 108, 164-169 (2007).
60. Charbonneau, F. et al. Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). Atherosclerosis 197, 420-427 (2008).
61. Turner, J., Belch, J. J. & Khan, F. Current concepts in assessment of microvascular endothelial function using laser Doppler imaging and iontophoresis. Trends Cardiovasc. Med. 18, 109-116 (2008).
62. Arosio, E. et al. Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis. J. Hypertens. 25, 1273-1278 (2007).
63. Newton, D. J., Khan, F. & Belch, J. J. Assessment of microvascular endothelial function in human skin. Clin. Sci. 101, 567-572 (2001).
64. Khan, F., Elhadd, T. A., Greene, S. A. & Belch, J. J. Impaired skin microvascular function in children, adolescents, and young adults with type 1 diabetes. Diabetes Care 23, 215-220 (2000).
65. Ijzerman, R. G. et al. Individuals at increased coronary heart disease risk are characterized by an impaired microvascular function in skin. Eur. J. Clin. Invest. 33, 536-542 (2003).
66. Khan, F., Patterson, D., Belch, J. J., Hirata, K. & Lang, C. C. Relationship between peripheral and coronary function using laser Doppler imaging and transthoracic echocardiography. Clin. Sci. 115, 295-300 (2008).
67. Huang, A. L. et al. Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. Arterioscler. Thromb. Vasc. Biol. 27, 2113-2119 (2007).
68. Wilkinson, I. B. et al. Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler. Thromb. Vasc. Biol. 22, 147-152 (2002).
69. Chowienczyk, P. J. et al. Photoplethysmographic assessment of pulse wave reflection: blunted response to endothelium-dependent beta2-adrenergic vasodilation in type II diabetes mellitus. J. Am. Coll. Cardiol. 34, 2007-2014 (1999).
70. Belch, J. J. et al. The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transluminal angioplasty. Circulation 95, 2027-2031 (1997).
71. Hope, S. A. & Meredith, I. T. Cellular adhesion molecules and cardiovascular disease. Part II. Their association with conventional and emerging risk factors, acute coronary events and cardiovascular risk prediction. Intern. Med. J. 33, 450-462 (2003).
72. McLaren, M., Elhadd, T. A., Greene, S. A. & Belch, J. J. Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Clin. Appl. Thromb. Hemost. 5, 21-24 (1999).
73. Felmeden, D. C., Blann, A. D., Spencer, C. G., Beevers, D. G. & Lip, G. Y. A comparison of flowmediated dilatation and von willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Blood Coagul. Fibrinolysis 14, 425-431 (2003).
74. Folsom, A. R. et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 100, 736-742 (1999).
75. Whincup, P. H. et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur. Heart J. 23, 1764-1770 (2002).
76. Avouac, J., Uzan, G., Kahan, A., Boileau, C. & Allanore, Y. Endothelial progenitor cells and rheumatic disorders. Joint Bone Spine 75, 131-137 (2008).
77. Ablin, J. N. et al. Effect of anti-TNFα treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci. 79, 2364-2369 (2006).
78. Hannawi, S., Marwick, T. H. & Thomas, R. Inflammation predicts accelerated brachial arterial wall changes in patients with recentonset rheumatoid arthritis. Arthritis Res. Ther. 11, R51 (2009).
79. Vaudo, G. et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann. Rheum. Dis. 63, 31-35 (2004).
80. Hänsel, S., Lässig, G., Pistrosch, F. & Passauer, J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 170, 177-180 (2003).
81. Kerekes G. et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol. 35, 398-406 (2008).
82. Stamatelopoulos, K. S. et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler. Thromb. Vasc. Biol. 29, 1702-1708 (2009).
83. Gonzalez-Juanatey, C. et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing longterm treatment with anti-tumor necrosis factor α antibody. Arthritis Rheum. 51, 447-450 (2004).
84. Hürlimann, D. et al. Anti-tumor necrosis factoralpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106, 2184-2187 (2002).
85. Bosello, S. et al. TNF-alpha blockade induces a reversible but transient Effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin. Rheumatol. 27, 833-839 (2008).
86. Gonzalez-Juanatey, C. et al. Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin. Exp. Rheumatol. 24, 309-312 (2006).
87. Bilsborough, W. et al. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol. Int. 26, 1125-1131 (2006).
88. Sidiropoulos, P. I. et al. Sustained improvement of vascular endothelial function during anti-TNFα treatment in rheumatoid arthritis patients. Scand. J. Rheumatol. 38, 6-10 (2009).
89. Gonzalez-Juanatey, C. et al. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy. Arthritis Rheum. 59, 1821-1824 (2008).
90. Flammer, A. J. et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 117, 2262-2269 (2008).
91. Syngle, A., Vohra, K., Kaur, L. & Sharma, S. Effects of spironolactone on endothelial dysfunction in rheumatoid arthritis. Scand. J. Rheumatol. 38, 15-22 (2009).
92. Mäki-Petäjä, K. M. et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J. Am. Coll. Cardiol. 50, 852-858 (2007).
93. Datta, D., Ferrell, w. R., Sturrock, R. D., Jadhav, S. T. & Sattar, N. Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 192, 391-395 (2007).
94. Galarraga, B., Khan, F., Kumar, P., Pullar, T. & Belch, J. J. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford) 47, 1780-1784 (2008).
95. Galarraga, B., Belch, J. J. C., Pullar, T., Ogston, S. & Khan, F. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy. J. Rheumatol. doi:10.3899/jrheum. 090417.
96. Lau, C. S., McLaren, M., Hanslip, J., Kerr, M. & Belch, J. J. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis. Ann. Rheum. Dis. 52, 643-649 (1993).
97. McLaren, M., Alkaabi, J., Connacher, M., Belch, J. J. & Valenete, E. Activated factor XII in rheumatoid arthritis. Rheumatol. Int. 22, 182-184 (2002).
98. Klimiuk, P. A., Fiedorczyk, M., Sierakowski, S. & Chwiecko, J. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand. J. Rheumatol. 36, 345-350 (2007).
99. Cobankara, V. et al. Successful treatment of rheumatoid arthritis is associated with a reduction in serum sE-selectin and thrombomodulin level. Clin. Rheumatol. 23, 430-434 (2004).
100. Galarraga, B., Mclaren, M., Kennedy, G. & Belch, J. J. E-selectin in rheumatoid arthritis [abstract 19]. Rheumatology (Oxford) 45 (Suppl. 1), i32 (2006).
101. McEntegart, A. et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 40, 640-644 (2001).
102. Wållberg-Jonsson, S., Cederfelt, M. & Rantapää Dahlqvist, S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J. Rheumatol. 27, 71-75 (2000).
103. Peters, M. J. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 69, 325-331 (2010).